ISSN 1662-4009 (online)

ey0019.11-3 | New findings in adipose tissue biology | ESPEYB19

11.3. Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis

Z Jiang , M Zhao , L Voilquin , Y Jung , MA Aikio , T Sahai , FY Dou , AM Roche , I Carcamo-Orive , JW Knowles , M Wabitsch , EA Appel , CL Maikawa , JP Camporez , GI Shulman , L Tsai , ED Rosen , CD Gardner , BM Spiegelman , KJ Svensson

katrinjs@stanford.edu Cell Metab 2021; 33(9): 1836–1852.e11http://www.ncbi.nlm.nih.gov/pubmed/34348115Brief Summary: This rodent study identified a novel adipokine in mice which triggers a signaling cascade similar to that of insulin. By acting via an unknown tyrosine kinase, isthmin-1 (ISM1) ameliorates metabolic disturbances associated wit...

ey0016.9-8 | Fertility Issues in Chronic Diseases: New Insights | ESPEYB16

9.8. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve

MH van den Berg , A Overbeek , CB Lambalk , GJL Kaspers , D Bresters , MM van den Heuvel-Eibrink , LC Kremer , JJ Loonen , HJ van der Pal , CM Ronckers , WJE Tissing , AB Versluys , M van der Heiden-van der Loo , AC Heijboer , M Hauptmann , JWR Twisk , JSE Laven , CCM Beerendonk , FE van Leeuwen , E van Dulmen-den Broeder , DCOG LATER-VEVO Study Group

Hum Reprod. 2018 Jul 6. [Epub ahead of print]. doi: 10.1093/humrep/dey229Childhood cancer treatment may compromise ovarian function in female childhood cancer survivors (CCSs), leading to delayed or arrested puberty, infertility, subfertility and adverse pregnancy outcomes. This Dutch nationwide retrospective cohort study collected measurements performed between 2008 and 2...

ey0017.8-12 | New Hope | ESPEYB17

8.12. HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma

J Zein , B Gaston , P Bazeley , MD DeBoer , RP Jr Igo , ER Bleecker , D Meyers , S Comhair , NV Marozkina , C Cotton , M Patel , M Alyamani , W Xu , WW Busse , WJ Calhoun , V Ortega , GA Hawkins , M Castro , KF Chung , JV Fahy , AM Fitzpatrick , E Israel , NN Jarjour , B Levy , DT Mauger , WC Moore , P Noel , SP Peters , WG Teague , SE Wenzel , SC Erzurum , N Sharifi

To read the full abstract: Proc Natl Acad Sci U S A. 2020; 117(4): 2187–2193. PMID: 31932420.Since their discovery ~70 years ago, glucocorticoids (GC) have been widely used to elicit a systemic anti-inflammatory response, and currently play a major role in the treatment of asthma and other inflammatory diseases (1). However, unresponsiveness to GC in some individuals i...

ey0018.4-13 | New Paradigms | ESPEYB18

4.13 A Genome-wide pharmacogenetic study of growth hormone responsiveness

A Dauber , Y Meng , L Audi , S Vedantam , B Weaver , A Carrascosa , K Albertsson-Wikland , M Ranke , A Jorge , J Cara , MP Wajnrajch , A Lindberg , C Camacho-Hübner , JN Hirschhorn

J Clin Endocrinol Metab. 2020;105:3203–3214. doi: 10.1210/clinem/dgaa443. PMID: 32652002The authors performed a large genome-wide association study (GWAS) to assess the role of common genetic variants in the response to GH therapy. A total of 614 children treated with GH were included: 276 with idiopathic GHD, 297 with ISS, and 41 born SGA. The findings implicate some novel mechanisms...

ey0019.8-9 | Clinical Trials – New Treatments | ESPEYB19

8.9. Tildacerfont in adults with classic Congenital Adrenal Hyperplasia: Results from two phase 2 studies

K Sarafoglou , CN Barnes , M Huang , EA Imel , IJ Madu , DP Merke , D Moriarty , S Nakhle , RS Newfield , MG Vogiatzi , RJ Auchus

J Clin Endocrinol Metab. 2021; 106(11): e4666-e4679. PMID: 34146101https://pubmed.ncbi.nlm.nih.gov/34146101/Brief Summary: These clinical trials evaluated the safety and efficacy of tildacerfront, a CRF1R antagonist, in suppressing adrenal androgen secretion in adult patients with classical Congenital adrenal hyperplasia (CAH) during a treatment period of 12 weeks.<p class="abs...

ey0017.4-11 | New perspectives | ESPEYB17

4.11. NPR2 Variants are frequent among children with familial short stature and respond well to growth hormone therapy

L Plachy , P Dusatkova , K Maratova , L Petruzelkova , D Zemkova , L Elblova , P Kucerova , L Toni , S Kolouskova , M Snajderova , Z Sumnik , J Lebl , S Pruhova

To read the full abstract: J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa037.This study aimed to assess the frequency of natriuretic peptide receptor type B gene (NPR2 ) variants in 87 children with familial short stature (FSS) and evaluate their response to GH therapy. By applying whole-exome or custom-targeted NGS panel sequencing, NPR2 variants were found in 5 children (5.7%) belonging to 4 families. These variants were cla...

ey0020.6-4 | Important for Clinical Practice | ESPEYB20

6.4. A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies

M Aranda-Guillen , EC Royrvik , S Fletcher-Sandersjoo , H Artaza , IR Botusan , MA Grytaas , AE Hallgren , L Breivik , M Pettersson , AP Jorgensen , A Lindstrand , E Vogt , Norwegian Addison Registry Study Group, The Swedish Addison Registry Study Group , ES Husebye , O Kampe , ASB Wolff , S Bensing , S Johansson , D Eriksson

Brief summary: The authors designed a polygenic risk score (PRS) to aid in estimating disease susceptibility in patients with autoimmune Addison’s disease (AAD).Autoimmune Addison’s disease (AAD) is the most common cause of primary adrenal insufficiency (PAI) in adults. Despite its exceptionally high heritability, tools to estimate disease susceptibility in individual patients are lacking (1–3). The aim of this study was t...

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 7–17 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...

ey0020.8-5 | Important for Clinical Practice | ESPEYB20

8.5. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries

NH Birkebaek , C Kamrath , JM Grimsmann , K Aakesson , V Cherubini , K Dovc , C de Beaufort , GT Alonso , JW Gregory , M White , T Skrivarhaug , Z Sumnik , C Jefferies , T Hortenhuber , A Haynes , M De Bock , J Svensson , JT Warner , O Gani , R Gesuita , R Schiaffini , R Hanas , A Rewers , AJ Eckert , RW Holl , O Cinek

Brief summary: This international multicentre study collected data from 104 290 children and adolescents (6 months-18 years-old), to compare prevalence of diabetic ketoacidosis (DKA) at diagnosis of type 1 diabetes (T1D) before and during the COVID-19 pandemic. Prevalence of DKA at T1D diagnosis increased from 27.3% pre-pandemic to 39.4% during the pandemic, and the increased trends were associated with the pandemic containment measures.DKA is a life-thr...

ey0020.9-7 | Genetic Obesity and Genetic Risk Score | ESPEYB20

9.7. Rare antagonistic leptin variants and severe, early-onset obesity

JB Funcke , B Moepps , J Roos , J von Schnurbein , K Verstraete , E Frohlich-Reiterer , K Kohlsdorf , A Nunziata , S Brandt , A Tsirigotaki , A Dansercoer , E Suppan , B Haris , KM Debatin , SN Savvides , IS Farooqi , K Hussain , P Gierschik , P Fischer-Posovszky , M Wabitsch

Brief summary: The authors provide the first description of antagonistic hormone mutations as the cause of congenital disease in humans. The paper describes detailed characterizations of two novel, antagonistic leptin mutations underlying a formerly unrecognized form of congenital leptin dysfunction and delineate the challenges these mutations pose to the diagnosis and therapy of the disease.After the initial description of biologically inactive leptin v...